Zydus Lifesciences gains on improved ALS drug prospects after Novartis exit

Zydus Lifesciences gained ground in afternoon trading after research firm Bernstein highlighted an improved commercial outlook for the company's amyotrophic lateral sclerosis (ALS) therapy. The uptick came as Swiss pharmaceutical major Novartis stepped back from its own ALS drug development, reducing competitive pressures in a niche but strategically important therapeutic segment.

Bernstein maintained its Outperform rating on Zydus Lifesciences, citing the clearer pathway for Usnoflast in the market. The exit by Novartis, a heavyweight competitor, removes a significant obstacle for the Indian firm's commercialisation plans. ALS, a progressive neurodegenerative disease, represents a critical market opportunity for specialty pharma players given unmet patient needs and limited treatment options.

The timing is significant as Zydus Lifesciences approaches key clinical data readouts for Usnoflast. Positive trial results could substantially strengthen the company's market position, particularly in developed markets where ALS treatments command premium pricing. The reduced competitive intensity improves the potential commercial runway for the drug.

For Indian pharmaceutical investors, the development underscores the growing importance of rare and specialty disease treatments as a growth driver for domestic drugmakers. As larger global competitors reallocate resources, Indian firms with focused development programmes in these niches stand to benefit from improved market dynamics and partner opportunities.